The Use of Integrated and Intelligent Testing Strategies in the Prediction of Toxic Hazard and in Risk Assessment

There is increasing concern that insurmountable differences between humans and laboratory animals limit the relevance and reliability for hazard identification and risk assessment purposes of animal data produced by traditional toxicity test procedures. A way forward is offered by the emerging new technologies, which can be directly applied to human material or even to human beings themselves. This promises to revolutionise the evaluation of the safety of chemicals and chemical products of various kinds and, in particular, pharmaceuticals. The available and developing technologies are summarised and it is emphasised that they will need to be used selectively, in integrated and intelligent testing strategies, which, in addition to being scientifically sound, must be manageable and affordable. Examples are given of proposed testing strategies for general chemicals, cosmetic ingredients, candidate pharmaceuticals, inhaled substances, nanoparticles and neurotoxicity.

[1]  R. W. Kapp,et al.  Toxic Substances Control Act , 2014 .

[2]  Zvia Agur,et al.  Use of Virtual Patient Populations for Rescuing Discontinued Drug Candidates and for Reducing the Number of Patients in Clinical Trials , 2009, Alternatives to laboratory animals : ATLA.

[3]  Michael Balls,et al.  A Frame Response to the European Commission Consultation on the Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects — 2010 a , 2010 .

[4]  Robert Combes,et al.  TGN1412: Time to Change the Paradigm for the Testing of New Pharmaceuticals , 2006, Alternatives to laboratory animals : ATLA.

[5]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[6]  T Seidle,et al.  The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. , 2007, Current pharmaceutical design.

[7]  N. Kaplowitz,et al.  Drug-induced liver injury. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Terrance J Kavanagh,et al.  Luminescent quantum dots for molecular toxicology. , 2012, Advances in experimental medicine and biology.

[9]  P. Watkins,et al.  The Application of Metabonomics to Predict Drug‐Induced Liver Injury , 2010, Clinical pharmacology and therapeutics.

[10]  Daniel A Casciano,et al.  The use of genomics in model in vitro systems. , 2012, Advances in experimental medicine and biology.

[11]  Kathryn A Phillips,et al.  Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. , 2007, Current drug safety.

[12]  Saber M Hussain,et al.  Toxicity testing of nanomaterials. , 2012, Advances in experimental medicine and biology.

[13]  D. Noble Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[14]  E. Kunkel Systems biology in drug discovery , 2004, Nature Biotechnology.

[15]  Robert Combes,et al.  An Integrated Decision-tree Testing Strategy for Repeat Dose Toxicity with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.

[16]  K. BéruBé,et al.  Alternatives for Lung Research: Stuck between a Rat and a Hard Place , 2011, Alternatives to laboratory animals : ATLA.

[17]  Ignazio Grattagliano,et al.  Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.

[18]  Judith C. Madden,et al.  In silico toxicology : principles and applications , 2010 .

[19]  D. L. Chesney Perspectives on GMP compliance in the production of clinical supplies , 1998 .

[20]  M. Miller Agency , 2010 .

[21]  Uwe Marx,et al.  Trends in cell culture technology. , 2012, Advances in experimental medicine and biology.

[22]  R D Combes,et al.  Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[24]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[25]  Robert Combes,et al.  Intelligent Testing Strategies for Chemicals Testing — A Case of More Haste, Less Speed? , 2005, Alternatives to laboratory animals : ATLA.

[26]  Robert Combes,et al.  In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. , 2009, Alternatives to laboratory animals : ATLA.

[27]  N. Thomas Review Article: High-Content Screening: A Decade of Evolution , 2010, Journal of biomolecular screening.

[28]  Michael P Holt,et al.  Drug-induced liver injury. , 2010, Handbook of experimental pharmacology.

[29]  Carl-Fredrik Mandenius,et al.  Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project , 2011, Alternatives to laboratory animals : ATLA.

[30]  Michael Balls,et al.  Integrated Testing Strategies for Toxicity Employing New and Existing Technologies , 2011, Alternatives to laboratory animals : ATLA.

[31]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[32]  T Hartung,et al.  Toward an evidence-based toxicology , 2006, Human & experimental toxicology.

[33]  Susanne Bremer,et al.  Embryonic stem cells in safety pharmacology and toxicology. , 2012, Advances in experimental medicine and biology.

[34]  L Hunt,et al.  The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health , 2011, Clinical pharmacology and therapeutics.

[35]  Michael Balls,et al.  Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application–and Back Again , 2012 .

[36]  Jehyuk Lee,et al.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.

[37]  Shayne C. Gad,et al.  Preclinical Development Handbook , 2008 .

[38]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[39]  Arti Ahluwalia,et al.  Engineering Quasi-Vivo in vitro organ models. , 2012, Advances in experimental medicine and biology.

[40]  Carol A Marchant,et al.  An Expert System Approach to the Assessment of Hepatotoxic Potential , 2009, Chemistry & biodiversity.

[41]  Robert Combes,et al.  Integrated Decision-tree Testing Strategies for Acute Systemic Toxicity and Toxicokinetics with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.

[42]  Jonathan Balcombe,et al.  Animal Carcinogenicity Studies: 2. Obstacles to Extrapolation of Data to Humans , 2006, Alternatives to laboratory animals : ATLA.

[43]  Seth Pettie,et al.  Mind the gap , 2006, Nature Reviews Drug Discovery.

[44]  Tsun-Po Yang,et al.  Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies , 2010, Bioinform..

[45]  Xudong Zhang,et al.  Medium to high throughput screening: microfabrication and chip-based technology. , 2012, Advances in experimental medicine and biology.

[46]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[47]  A. Abate,et al.  Ultrahigh-throughput screening in drop-based microfluidics for directed evolution , 2010, Proceedings of the National Academy of Sciences.

[48]  Robert D Combes,et al.  In silico methods for toxicity prediction. , 2012, Advances in experimental medicine and biology.

[49]  Epic Admin Who we regulate , 2007 .

[50]  Andrew Worth,et al.  Overcoming Barriers to Validation of Non-animal Partial Replacement Methods/Integrated Testing Strategies: The Report of an EPAA–ECVAM Workshop , 2009, Alternatives to laboratory animals : ATLA.

[51]  Oa,et al.  Summary of the Toxic Substances Control Act , 2013 .

[52]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[53]  William M. Lee,et al.  Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.

[54]  Michael Balls,et al.  Translation of new technologies: from basic research to drug discovery and development. , 2008, Current drug discovery technologies.

[55]  D. L. Taylor,et al.  A Personal Perspective on High-Content Screening (HCS) , 2010, Journal of biomolecular screening.

[56]  T. Hartung Toxicology for the twenty-first century , 2009, Nature.

[57]  Robert Combes,et al.  Preclinical Drug Development Planning , 2010 .

[58]  M. Eileen Dolan,et al.  Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci , 2010, Proceedings of the National Academy of Sciences.

[59]  M. Balls Chapter 23:Integrated Testing Strategies and the Prediction of Toxic Hazard , 2010 .

[60]  Kannan Krishnan,et al.  Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.

[61]  Robert Combes,et al.  An Integrated Decision-tree Testing Strategy for Skin Sensitisation with Respect to the Requirements of the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.

[62]  Johannes Doehmer The Use and Value of In Vitro Technologies in Metabolism Studies , 2009, Alternatives to laboratory animals : ATLA.

[63]  H. Hogberg,et al.  Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered. , 2010, Neurotoxicology and teratology.

[64]  K. Shakesheff,et al.  Tissue engineering in the development of replacement technologies. , 2012, Advances in experimental medicine and biology.

[65]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[66]  Michael Balls Modern Alternative Approaches to the Problem of Drug-induced Liver Injury , 2011, Alternatives to laboratory animals : ATLA.

[67]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[68]  Robert Combes,et al.  An Integrated Decision-tree Testing Strategy for Eye Irritation with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.

[69]  Robert Combes,et al.  Proposed Integrated Decision-tree Testing Strategies for Mutagenicity and Carcinogenicity in Relation to the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.

[70]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[71]  Simon Thomas,et al.  Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals , 2009, Alternatives to laboratory animals : ATLA.

[72]  Robert Combes,et al.  Integrated Decision-tree Testing Strategies for Environmental Toxicity with Respect to the Requirements of the EU REACH Legislation , 2006, Alternatives to laboratory animals : ATLA.

[73]  Christina Grindon,et al.  Integrated Testing Strategies for Use in the EU REACH System , 2006, Alternatives to laboratory animals : ATLA.

[74]  A. Corrias,et al.  Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[75]  Robert Combes,et al.  A Scientific and Animal Welfare Assessment of the OECD Health Effects Test Guidelines for the Safety Testing of Chemicals under the European Union REACH System , 2004, Alternatives to laboratory animals : ATLA.

[76]  Glyn Stacey,et al.  Current developments in cell culture technology. , 2012, Advances in experimental medicine and biology.

[77]  Steven K. Gibb Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.

[78]  Robert Combes,et al.  Integrated Decision-tree Testing Strategies for Developmental and Reproductive Toxicity with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.

[79]  Robert Combes,et al.  An Integrated Decision-tree Testing Strategy for Skin Sensitisation with Respect to the Requirements of the EU REACH Legislation , 2008, Alternatives to laboratory animals : ATLA.

[80]  Arun V Holden Development and Application of Human Virtual Excitable Tissues and Organs: From Premature Birth to Sudden Cardiac Death , 2010, Alternatives to laboratory animals : ATLA.

[81]  Aniruddh Solanki,et al.  A Step Closer to Complete Chemical Reprogramming for Generating iPS Cells , 2010, Chembiochem : a European journal of chemical biology.

[82]  Thomas Hartung,et al.  The value of alternative testing for neurotoxicity in the context of regulatory needs. , 2006, Environmental toxicology and pharmacology.

[83]  Robert Combes,et al.  Toxicity testing: creating a revolution based on new technologies. , 2005, Trends in biotechnology.

[84]  J. Valentin,et al.  An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk , 2010, British journal of pharmacology.

[85]  山上 鋭享 Globally Harmonized System of Classification and Labelling of Chemicals (GHS) 化学品の分類および表示に関する世界調和システム , 2007 .

[86]  Christina Grindon,et al.  Integrated Decision-tree Testing Strategies for Skin Corrosion and Irritation with Respect to the Requirements of the EU REACH Legislation , 2007, Alternatives to laboratory animals : ATLA.

[87]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.